Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health
innovation, announced today that William H. Rastetter, Ph.D., a
current member of its Board of Directors, was appointed Chairman of
its Board of Directors effective July 11, 2019.
“We are honored to have an industry luminary like Bill serve as
Chairman,” said Sabrina Martucci Johnson, President and CEO of Daré
Bioscience. “We are truly grateful to Roger Hawley, our
outgoing Chairman and co-founder of Daré, for his deep commitment
to our company and for his guidance and unwavering support from day
one.”
“I believe Daré is poised to deliver on a number of significant
milestones over the next 12 to 24 months. I am stepping off
the board for personal reasons and fully support the company and
the board changes. Bill’s wealth of experience and formidable
track record of success in biotech will be instrumental in guiding
Daré through its next stage of growth, and I look forward to
following the company’s developments,” said Roger Hawley.
Among his other awards and recognitions, Dr. Rastetter won the
Biotechnology Heritage Award in 2018, an award that recognizes
individuals who have made significant contributions to the
development of biotechnology through discovery, innovation, and
public understanding, for his work as co-inventor of Rituxan®, the
first monoclonal antibody (MAb) approved by the U.S. FDA for cancer
therapy.
Dr. Rastetter has been involved in the biotech industry for more
than 37 years in various capacities, including serving as the chief
executive and chairman of the board of numerous companies, and
being an advisor to investment banking and venture capital focused
on the industry. Among his other successful accomplishments, Dr.
Rastetter served as the Chairman and CEO of IDEC Pharmaceuticals
Corp. and was instrumental in leading the multi-billion dollar
merger of equals between IDEC and Biogen, Inc. He was
Chairman of Illumina Inc. from 2005 to 2016 and helped maintain the
company’s independence in the face of hostile takeover interests.
Dr. Rastetter was also Chairman and cofounder of Receptos, Inc.,
which was acquired by Celgene Corporation in 2015 for $7.2
billion.
Dr. Rastetter holds a Ph.D. and a Masters of Arts in Chemistry
from Harvard University and a Bachelor of Science in Chemistry from
Massachusetts Institute of Technology.
About Daré Bioscience
Daré Bioscience is a clinical-stage biopharmaceutical company
committed to the advancement of innovative products for women’s
health. The company’s mission is to identify, develop and bring to
market a diverse portfolio of differentiated therapies that expand
treatment options, improve outcomes and facilitate convenience for
women, primarily in the areas of contraception, vaginal health,
sexual health, and fertility.
Daré’s product portfolio includes potential first-in-category
candidates in clinical development: Ovaprene®, a non-hormonal,
monthly contraceptive intravaginal ring; Sildenafil Cream, 3.6%, a
novel cream formulation of sildenafil to treat female sexual
arousal disorder utilizing the active ingredient in Viagra®;
DARE-BV1, a unique hydrogel formulation of clindamycin phosphate 2%
to treat bacterial vaginosis via a single application; and
DARE-HRT1, a combination bio-identical estradiol and progesterone
intravaginal ring for hormone replacement therapy following
menopause. To learn more about Daré’s full portfolio of women’s
health product candidates, and mission to deliver differentiated
therapies for women, please visit www.darebioscience.com.
Daré may announce material information about its finances,
product candidates, clinical trials and other matters using its
investor relations website
(http://ir.darebioscience.com), SEC filings, press
releases, public conference calls and webcasts. Daré uses
these channels to communicate with its investors and the public
about the company and other company-related matters. The
information Daré posts on its investor relations website may be
deemed to be material information. Daré encourages investors, the
media, and others interested in the company to review the
information Daré posts on its investor relations
website: www.darebioscience.com.
Forward-Looking Statements
Daré cautions you that all statements, other than statements of
historical facts, contained in this press release, are
forward-looking statements. Forward-looking statements, in some
cases, can be identified by terms such as “believe,” “may,” “will,”
“estimate,” “continue,” “anticipate,” “design,” “intend,” “expect,”
“could,” “plan,” “potential,” “predict,” “seek,” “should,” “would,”
“contemplate,” project,” “target,” “tend to,” or the negative
version of these words and similar expressions. Such statements
include, but are not limited to, statements relating to Daré’s
ability to deliver on significant milestones. Forward-looking
statements involve known and unknown risks, uncertainties and other
factors that may cause Daré’s actual results, performance or
achievements to be materially different from future results,
performance or achievements expressed or implied by the
forward-looking statements in this press release, including,
without limitation, risk and uncertainties related to: Daré’s
ability to raise additional capital when and as needed, to advance
its product candidates; Daré’s ability to develop, obtain
regulatory approval for, and commercialize its product candidates;
the failure or delay in starting, conducting and completing
clinical trials or obtaining FDA or foreign regulatory
approval for Daré’s product candidates in a timely manner; Daré’s
ability to conduct and design successful clinical trials, to enroll
a sufficient number of patients, to meet established clinical
endpoints, to avoid undesirable side effects and other safety
concerns, and to demonstrate sufficient safety and efficacy of its
product candidates; Daré’s ability to retain its licensed rights to
develop and commercialize a product candidate; Daré’s ability to
satisfy the monetary obligations and other requirements in
connection with its exclusive, in-license agreements covering the
critical patents and related intellectual property related to its
product candidates; developments by Daré’s competitors that make
its product candidates less competitive or obsolete; Daré’s
dependence on third parties to conduct clinical trials and
manufacture clinical trial material; Daré’s ability to adequately
protect or enforce its, or its licensor’s, intellectual property
rights; the lack of patent protection for the active ingredients in
certain of Daré’s product candidates which could expose its
products to competition from other formulations using the same
active ingredients; the risk of failure associated with product
candidates in preclinical stages of development that may lead
investors to assign them little to no value and make these assets
difficult to fund; and disputes or other developments concerning
Daré’s intellectual property rights. Daré’s forward-looking
statements are based upon its current expectations and involve
assumptions that may never materialize or may prove to be
incorrect. All forward-looking statements are expressly qualified
in their entirety by these cautionary statements. For a detailed
description of Daré’s risks and uncertainties, you are encouraged
to review its documents filed with the SEC including
Daré’s recent filings on Form 8-K, Form 10-K and Form 10-Q. You are
cautioned not to place undue reliance on forward-looking
statements, which speak only as of the date on which they were
made. Daré undertakes no obligation to update such statements to
reflect events that occur or circumstances that exist after the
date on which they were made, except as required by law.
Contacts:
Investors on behalf of Daré Bioscience, Inc.: Lee Roth
Burns McClellan lroth@burnsmc.com 212.213.0006
OR
Media on behalf of Daré Bioscience, Inc.: Jake Robison
Canale Communications jake@canalecomm.com 619.849.5383
Source: Daré Bioscience
Dare Bioscience (NASDAQ:DARE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Dare Bioscience (NASDAQ:DARE)
Historical Stock Chart
From Apr 2023 to Apr 2024